BofA raises Liquidia stock price target on strong PAH momentum
BofA Securities raised its price target for Liquidia Technologies (LQDA) to $54 from $42, citing strong momentum in Yutrepia PAH sales. The company reported Q3 revenue of $225.3M, beating estimates, and Yutrepia sales of $222.7M. Multiple analysts increased their price targets, with varying ratings.
How this was made
The 30-second read
Why it matters
Analyst upgrades and higher price targets reflect confidence in Yutrepia sales momentum, but the large settlement charge remains a downside risk.
Market read
The new target may drive short‑term buying interest, while the settlement charge tempers enthusiasm.
What to watch
Potential regulatory risk around PH‑ILD patent deal may limit future growth.
Background
Liquidia Technologies reported Q3 revenue of $225.3 million, beating expectations, with a $2.64 loss per share due to a $389.7 million settlement.
Ticker impact
BofA Securities raised its price target on Liquidia Technologies to $54 from $42 after the company's Q3 results showing strong Yutrepia sales.
likely upward pressure as the market prices in the higher target.
The new $54 target is above the current price of $51.40, indicating analysts see further upside.
Market effects
Positive signal for the biotech/rare disease sector as a major player shows strong sales momentum.
Limited to US biotech equities.
Modest, confined to investors tracking specialty pharma.
Counterpoint
The settlement charge and EPS loss could weigh on the stock despite the target raise.
Key entities
- companyLiquidia Technologies
Biotech firm developing inhaled treprostinil (Yutrepia).
- analystBofA Securities
Raised price target to $54.
